-
公开(公告)号：EP4302763A1
公开(公告)日：2024-01-10
申请号：EP22762608.2
申请日：2022-03-03
发明人： FENG, Fan , YU, Ding , WANG, Xunqiang , ZHANG, Xiquan , BAI, Yanfeng , YANG, Chaoqiang , ZHANG, Yuying
IPC分类号： A61K31/565 , C07D403/14 , A61P35/00
摘要： The present disclosure relates to a combined pharmaceutical composition containing a CDK4/6 inhibitor and a use thereof, and specifically relates to a combined pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and fulvestrant. The present disclosure further relates to a use of the combined pharmaceutical composition in treating breast cancer. The combined pharmaceutical composition of the present disclosure produces better therapeutic effects in reducing tumor growth or even eliminating tumors.
-
公开(公告)号：EP4159238A1
公开(公告)日：2023-04-05
申请号：EP21817364.9
申请日：2021-06-01
申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. , Tianjin Medical University Cancer Institute and Hospital
发明人： ZHANG, Xiquan , WANG, Xunqiang , YU, Ding , LIU, Tao , ZHAN, Xiaole , WU, Naiying
IPC分类号： A61K39/395 , C07D215/22 , C07K16/28 , A61P35/00
摘要： Provided are a combined pharmaceutical composition of an anti-PD-L1 antibody and a c-Met kinase inhibitor, specifically, a combined pharmaceutical composition of an anti-PD-L1 antibody and N-(4-((7-((1-(cyclopentylamino)cyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-3-fluorophenyl)-N-(4-f luorophenyl)cyclopropane-1,1-dicarboxamide, and the use of the combined pharmaceutical composition in the treatment of cancers, in particular, gastric cancer or liver cancer.
-
公开(公告)号：EP3858832A1
公开(公告)日：2021-08-04
申请号：EP19878278.1
申请日：2019-10-29
发明人： LIU, Fei , FENG, Weiwei , WANG, Bin , XU, Hongjiang , WANG, Jinan , ZHANG, Xiquan , WANG, Shanchun , LIU, Yanlong , ZHANG, Jianqing , YAO, Yiyan , TANG, Xujing , SHI, Wei , ZHANG, Hongying , LI, Yang , TANG, Song , ZHU, Yizhong , LIU, Limin , GU, Hongmei , YANG, Ling
IPC分类号： C07D471/04 , C07D211/96 , C07D215/20 , A61K31/404 , A61P35/00
摘要： Disclosed is a trifluoromethyl-substituted sulfonamide BCL-2-selective inhibitor, in particular disclosed are a compound of formula I, a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition thereof. Also disclosed are the uses of said compound and of a pharmaceutical composition comprising same for treating anti-apoptotic BCL-2-related diseases, such as cancer.
-
公开(公告)号：EP3590944A1
公开(公告)日：2020-01-08
申请号：EP18760796.5
申请日：2018-02-28
发明人： XIONG, Jian , XIE, Cheng , CHEN, Kevin X , XU, Xiongbin , ZHANG, Xuejin , GONG, Zhen , LI, Jian , CHEN, Shuhui , ZHANG, Aiming , JIANG, Zhulian , ZHANG, Xiquan , TIAN, Xin
摘要： Disclosed in the present application are a compound represented by formula (I), or a pharmaceutically acceptable salt, a tautomer thereof, a stereoisomer thereof, or a geometrical isomer thereof, and uses thereof in the preparation of drugs for treating or preventing multiple myeloma.
-
公开(公告)号：EP3272746B1
公开(公告)日：2019-12-25
申请号：EP16767717.8
申请日：2016-03-18
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Centaurus BioPharma Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： ZHANG, Xiquan , TANG, Song , FENG, Weiwei , TIAN, Xin , CHEN, Zhilin , GU, Hongmei , XU, Hongjiang , LIU, Fei
IPC分类号： C07D403/12 , C07D401/12 , C07D405/14 , A61K31/517 , A61K31/5377 , A61P35/00 , A61K31/4427 , A61K45/06 , C07D239/94 , C07D211/40
-
6.发明公开
公开(公告)号：EP3502103A1
公开(公告)日：2019-06-26
申请号：EP17848166.9
申请日：2017-09-08
发明人： DING, Charles Z. , CHEN, Shuhui , HU, Lihong , XU, Zhaobing , LIU, Yingchun , REN, Bingjie , LI, Weidong , LI, Zongbin , ZHAO, Rui , ZHANG, Xiquan
IPC分类号： C07D401/14 , A61K31/506 , A61P35/00
摘要： A crystal form and a salt type of a substituted 2-hydro-pyrazole derivative, preparation method therefor, and use of the crystal form and the salt type in preparation of a medicament for treating cancers such as breast cancer, lung cancer and the like.
-
公开(公告)号：EP3498704A1
公开(公告)日：2019-06-19
申请号：EP17838796.5
申请日：2017-08-11
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： SANG, Guangming , LIU, Lin , ZHANG, Aiming , QIAO, Jiabin , GUO, Xiaopeng , ZHANG, Xiquan , XIA, Chunguang
IPC分类号： C07D405/04 , A61K31/4035 , A61P5/50 , A61P3/00 , A61P35/00 , A61P25/00 , A61P3/12
摘要： The present application relates a crystal of a compound represented by Formula (I), a salt thereof, and a crystal of the salt thereof, a method for preparing the crystal of the compound represented by Formula (I), the salt thereof, and the crystal of the salt thereof, a crystal comprising the compound represented by Formula (I), a crystal composition comprising the crystal of the salt thereof, a pharmaceutical composition thereof, and medical uses thereof.
-
公开(公告)号：EP3473626A1
公开(公告)日：2019-04-24
申请号：EP17812741.1
申请日：2017-06-15
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： ZHOU, Zhou , ZHANG, Aiming , ZHANG, Xiquan , YAO, Huadong
IPC分类号： C07D487/04 , A61K31/519 , A61K31/5377 , A61P35/00
摘要： The present application relates to the field of pharmaceutical chemistry. The application specifically relates to a crystal form A and crystal form B of a pyrrolopyrimidine (formula I) for preparing a JAK inhibitor. The application further relates to a method for preparing the crystal form A and crystal form B, a crystalline composition comprising the crystal form A or crystal form B, a pharmaceutical composition comprising the crystal form A, crystal form B, or crystalline composition, and a pharmaceutical application of the pharmaceutical composition, the crystal form A, and the crystal form B. The crystal form A and crystal form B of the application has the advantages of high purity, high crystallinity, and good stability.
-
公开(公告)号：EP3473625A1
公开(公告)日：2019-04-24
申请号：EP17812738.7
申请日：2017-06-15
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： ZHANG, Xiquan , ZHANG, Aiming , ZHOU, Zhou , YAO, Huadong , XIE, Jie
IPC分类号： C07D487/04
摘要： Provided are a preparation method for a chiral pyrrolopyrimidine compound and a related intermediate. In the method, a compound of formula A and a compound of formula 6 or a salt thereof are reacted to obtain a compound of formula 7 or a compound of formula 14, and a compound of formula I is prepared from the compound of formula 7 or the compound of formula 14. Also provided are the intermediate used, a preparation method for the intermediate and a use of the intermediate in the preparation of the compound of formula I. The preparation method has characteristics such as brief steps, a high stereoselectivity, a high utilization ratio of atoms, mild reaction conditions and a convenient post-treatment. The method avoids using an expensive asymmetric reaction catalyst, and is suitable for industrial production.
-
公开(公告)号：EP3330263A1
公开(公告)日：2018-06-06
申请号：EP16829888.3
申请日：2016-07-29
申请人： Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： WANG, Shulong , ZHAO, Na , LIU, Xijie , HU, Yuandong , ZHANG, Hui , LUO, Hong , PENG, Yong , XIAO, Dengming , HAN, Yongxin , ZHANG, Xiquan , TIAN, Xin
IPC分类号： C07D333/24 , C07D409/12 , C07D213/56 , C07C275/42 , C07D231/12 , C07D409/10 , C07D333/20 , A61P35/00 , A61P35/02
摘要： The present application relates to compounds represented by general formula (I), general formula (II) or general formula (III), and pharmaceutically acceptable salts or hydrates thereof, preparation methods thereof, and pharmaceutical compositions thereof. The compounds represented by general formula (I), general formula (II) or general formula (III) have inhibitory activities against isocitrate dehydrogenase 2 (IDH2), thereby being capable of treating IDH2 mutation-induced cancers.
-
-
-
-
-
-
-
-
-
搜索结果
64 条记录 (耗时 0.031 秒)
